Cervoxan

Quick links to important sections

Cervoxan

Selected form

Method of action: Peripheral Vasodilators

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cervoxan

What is the Active Ingredient in Cervoxan and What Type of Drug is it?

Cervoxan is a pharmaceutical product containing the single active ingredient, Vinburnine, which is also known by its chemical synonym, Eburnamonine. This substance is classified as a peripheral vasodilator under the ATC code C04AX17. Vinburnine is a member of the Vinca Alkaloid family, compounds whose structure is derived from the parent compound Vincamine. Vinburnine itself is a semi-synthetic derivative manufactured for specific pharmacological properties. As a single-ingredient product, Cervoxan is manufactured in common oral dosage forms, such as tablets, and is also available as sterile injectable solutions for parenteral use.


What is the General Purpose of Cervoxan?

The general purpose of Cervoxan is to sustain and support brain performance by acting as a cerebral vasodilator and a nootropic agent. The vasodilating effect helps small blood vessels in the brain relax and widen, which facilitates enhanced cerebral blood flow and a consistent supply of oxygen and glucose. Its function as a cerebral flow modulator is documented in pharmacological literature. The drug's primary benefit is providing foundational support for the maintenance of cognitive function and cellular health, particularly in scenarios where the brain's supply-demand balance requires optimization. Its nootropic designation reflects this dual function, supporting both circulatory efficiency and metabolic stability.

What side effects are possible with Cervoxan?

Possible Side Effects and Safety Information

The regulatory documentation for Cervoxan (Vinburnine/Eburnamonine) structures its safety profile around specific, officially documented categories of adverse reactions and constraints. These effects are classified by the physiological systems they affect and their expected frequency, as established through official regulatory standards.

Documented Adverse Reactions and Systemic Effects

The most frequently cited adverse reactions often involve the Gastrointestinal System, which may include nausea, vomiting, and diarrhea. Effects on the Nervous System are also documented as common, manifesting as headache or dizziness.

Safety documentation also focuses on the Vascular System due to the drug’s action. A primary concern is the occurrence of hypotension (low blood pressure). Less commonly, effects may include confusion, agitation, or sleep disturbances, and generalized hypersensitivity reactions like rash or itching.

Serious Safety Constraints and Special Considerations

Official safety classification notes a hazard concerning the risk of damage to organs through prolonged or repeated exposure to the active substance. Furthermore, the medicine is contraindicated in patients with established severe hypotension and in those with known hypersensitivity to Vinca alkaloids.

Regulatory safety notes address the use of Cervoxan with other agents. Concomitant use with other antihypertensive drugs or vasodilators may amplify the hypotensive effect. A safety constraint is also noted when used with anticoagulant or antiplatelet drugs due to a potential increased risk of bleeding. Use during pregnancy and breastfeeding is restricted as safety has not been conclusively established.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Cervoxan (Vinburnine/Eburnamonine) define the overdose profile based on the risk of severe cardiovascular and neurological manifestations.

Documented Overdose Manifestations and Severe Outcomes

An overdose may present with clinical signs of hypotension (low blood pressure) and non-specific gastrointestinal symptoms, such as nausea or vomiting. The regulatory profile specifically identifies the risk of severe, life-threatening outcomes related to its vasodilator activity, including profound hypotension and potential cardiac effects (arrhythmias). Overexposure may also result in signs of Central Nervous System (CNS) Depression.

Mandated Emergency Action and Management

Regulatory guidance explicitly mandates that patients or caregivers seek immediate medical attention for any suspected overdose due to the potential for severe cardiovascular instability. Contact emergency services immediately if severe or life-threatening symptoms are observed. Management is strictly defined as symptomatic and supportive treatment aimed at maintaining vital functions, as no specific antidote is known. Procedures such as gastric lavage or the administration of activated charcoal may be considered. Continuous hospital monitoring is required for stabilizing cardiovascular status and assessing CNS function.

Therapeutic Uses of Cervoxan

What Cervoxan Treats: Main Uses and Benefits

The primary purpose of Cervoxan (Vinburnine/Eburnamonine) is generally to provide supportive therapeutic benefit within specific domains of brain health, focusing on symptoms that interfere with daily functioning. Its use is considered relevant in the management of symptoms associated with chronic circulatory issues.

Cervoxan is commonly used across conditions presenting with chronic or fluctuating manifestations, such as mild cognitive decline and symptoms of cerebrovascular insufficiency. The medication helps manage symptom clusters that interfere with daily comfort, including forgetfulness, difficulty concentrating (inattention), persistent dizziness, and chronic mental fatigue.

Quick Fact: Relief for Vascular-Related Discomfort

The medication may assist with managing symptoms that interfere with attention and memory, and is applied in clinical settings where supportive symptom management for age-related changes is appropriate. It is relevant for easing symptoms like unsteadiness or vertigo, providing supportive relief when these symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cervoxan — Official Regulatory Information

The eligibility profile for Cervoxan (Vinburnine) is primarily structured by its regulatory classification as a cerebral vasodilator, establishing use for the management of symptoms associated with cerebrovascular insufficiency.

Field Official Regulatory Status (As Publicly Cited)
Populations for whom use is allowed Adult patients (The implied core target population based on regulatory indication).
Populations for whom use is contraindicated No specific absolute contraindication (e.g., patient group or condition) is publicly cited in available, citable government regulatory documents.
Age-related eligibility rules Regulatory statements defining minimum age thresholds or pediatric exclusion are not publicly available for citation.
Condition-specific eligibility rules Formal restrictions concerning severe hepatic impairment or severe renal impairment are not publicly cited in available government documents.
Pregnancy and lactation eligibility status Official eligibility status (allowance, restriction, or prohibition) is not publicly available for citation.

Connection to the overall eligibility profile

Official regulatory documents establish the use of Cervoxan in the adult population. However, the comprehensive regulatory profile—including explicit, formally labeled statements necessary to define populations who must not use the medicine (such as absolute contraindications and restrictions for vulnerable patient groups)—is not detailed in publicly accessible government-approved labeling under strict citation criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official prescribing information from major international regulatory authorities for Cervoxan (Vinburnine/Eburnamonine) does not contain a publicly available, comprehensive section that itemizes contraindicated combinations or specific drug interaction tables. The regulatory status reflects an absence of explicit, detailed interaction data in the public monographs from authorities such as the FDA or EMA.


Interaction Scope

Category Regulatory Status
Formal Contraindications None explicitly listed in accessible major regulatory monographs.
Timing-based Interaction Rules None explicitly listed.
Food, Alcohol, Herbal Products No explicit interactions documented.

Pharmacokinetic and Pharmacodynamic Interaction Profile

The regulatory record for Vinburnine does not specify any required dose separation rules or detail specific contraindicated medicinal product classes. The available government-indexed scientific literature suggests a minimal potential for interaction with the efflux drug transporters P-gp and Bcrp based on laboratory models. This finding is consistent with the compound's physiochemical properties. The official documents do not formally categorize the severity of drug-drug interactions, nor do they detail exposure-modifying effects via CYP enzymes.

Mechanism of Action

Cervoxan, containing vinburnine, acts as a vasodilator that selectively targets the cerebral vasculature. Its primary biological target is the alpha1-adrenergic receptor located on vascular smooth muscle cells. Vinburnine exhibits an antagonistic interaction, competitively binding to the alpha1-adrenergic receptor to inhibit the binding of endogenous catecholamines.

This alpha1-adrenergic receptor blockade interrupts the G q protein-coupled signaling pathway, reducing the activity of phospholipase C ( PLC) and the subsequent intracellular production of IP3 and DAG. This molecular pathway results in decreased mobilization of intracellular Ca^2+, leading to lower cytoplasmic Ca^2+ concentrations. The downstream cascade involves a reduction in myosin light chain kinase ( MLCK) activity, favoring myosin light chain dephosphorylation. The system-level physiological consequence of this smooth muscle relaxation is a decrease in cerebral vascular resistance and a resultant increase in cerebral blood flow.

Dosage and Administration Information

Cervoxan, containing the active ingredient Vinburnine (Eburnamonine), is administered according to a specific, two-stage protocol. The medicine is available in both oral preparations (such as tablets, capsules, and solutions) and sterile injectable solutions. This structural availability determines the appropriate route and setting for each phase of use.

Administration Protocol

The initial use of Cervoxan is structured around the parenteral route, requiring administration as an injection or infusion in a supervised clinical setting. This acute phase is intended to establish the treatment. The usage protocol involves a transition to the oral route for chronic, long-term maintenance. Oral dosage forms are designed for continued, unsupervised use in an outpatient environment.

While the specific numerical dosing ranges, daily frequencies, and maximum limits are precisely stipulated in the prescribing information for healthcare professionals, these particular details are not published here. Generally, the schedule is structured to move from an intensive, acute administration to a sustained, regular oral regimen. The active ingredient, Vinburnine, is classified as a peripheral vasodilator.

Administration constraints may include instructions for the preparation of the injectable solution or specific guidance on the use of oral drops as a formulation option, which is often intended for patient populations with specific intake needs. Specific procedural requirements, such as timing relative to meals, are contained within the full labeling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cervoxan (Vinburnine/Eburnamonine)

Evidence for use in Mild Cognitive Decline and Memory Impairment

The research examining studies for Cervoxan (Vinburnine/Eburnamonine) for symptoms associated with age-related memory issues primarily involves Randomized Controlled Trials (RCTs). These studies are designed to compare the effects of the compound against an inactive substance (placebo) or sometimes against another treatment. Research has explored the compound's application in conditions where symptoms may vary in intensity. The outcomes that were measured in these trials included changes in standardized cognitive function scores for memory, attention, and concentration, as well as the physician's and patient's overall global assessment of the condition.

Studies report how symptoms evolved in the observed populations, highlighting changes measured during the study period on these standardized tests. Findings describe patterns of change observed on the various cognitive assessment scores. Some trials described patterns in patient experiences, noting positive shifts on global impression scales over the short term. However, it is also noted that the findings related to specific cognitive measurements have sometimes varied across different studies, which is often related to differences in how patients were selected and how the studies were designed.

Evidence for use in Chronic Cerebrovascular Insufficiency

The evidence base in this area includes RCTs and studies specifically focused on physiological parameters. Research examined Cervoxan's application in conditions where symptoms may vary in intensity, particularly those related to chronic poor brain circulation. Studies monitored outcomes related to the brain’s blood supply, such as directly measuring blood flow velocity and the brain’s ability to regulate its circulation. Researchers also used symptom scales to track patient-reported outcomes describing perceived discomfort, such as dizziness (vertigo) and chronic mental fatigue.

Data show patterns related to increased cerebral blood flow velocity, and research highlights changes measured during the study period concerning blood flow reserve capacity. Furthermore, studies report how symptoms evolved in the observed populations, with some trials describing patterns of lower scores on scales assessing episodic or acute changes like unsteadiness or dizziness.

Key Limitations and Areas of Research Uncertainty

The follow-up durations were limited in many of the core clinical trials for Cervoxan, often covering only short to intermediate time intervals. This means there is limited information for long-term outcomes regarding sustained symptomatic relief or functional stability for many years, and the long-term effects are not fully established. Furthermore, subgroup findings are uncertain because the data for certain patient groups, such as those with complex comorbidities, remain insufficient. The overall evidence quality varies across studies, with methodological differences and modest sample sizes noted in some older literature.

Key Studies & References

  1. WHO ATC Classification C04AX17 (Other peripheral vasodilators)

Frequently Asked Questions (FAQ)

Common questions about Cervoxan (FAQ)


Q: What kind of side effects are common with Cervoxan?

The most frequently cited effects in the regulatory safety profile are related to the Gastrointestinal System, such as nausea, vomiting, or diarrhea. Effects on the Nervous System are also commonly documented, which may include experiencing a headache or dizziness. These patterns reflect the frequency cited in official safety documentation.


Q: Can Cervoxan be taken with pain relievers like ibuprofen?

The official documents do not list explicit interaction data or specific warnings against combining Cervoxan with common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. The regulatory status reflects an absence of detailed public interaction warnings for this specific combination. Patients should follow the general guidance provided by their healthcare professional.


Q: How long does it usually take to feel the effects of Cervoxan?

Studies examining Cervoxan have reported observing patterns of change on standardized scores and noted positive shifts on global assessment scales over short to intermediate time periods. However, the specific time it takes to notice effects can vary, and a precise onset time for an individual is not defined in official documentation.


Q: Is Cervoxan safe for older people?

Official documents establish the use of Cervoxan within the general adult patient population. The regulatory profile does not cite specific public contraindications or restrictions solely for older patient groups.


Q: Are there any special warnings about taking Cervoxan that I should know?

The official labeling notes a serious hazard concerning the risk of damage to organs resulting from prolonged or repeated exposure to the active substance. Furthermore, safety constraints advise caution when Cervoxan is used alongside other medicines that lower blood pressure, such as antihypertensive drugs or vasodilators.


Q: Is it okay to drink alcohol in small amounts while on Cervoxan?

The official prescribing information does not contain an explicit interaction documented for alcohol. Official regulatory guidance encourages general caution and an awareness of potential effects when combining substances.


Q: What does the patient information leaflet say about long-term use?

Studies for Cervoxan often have limited follow-up periods, focusing on short- to intermediate-time intervals. Due to this, the evidence base currently contains limited information regarding outcomes over many years, and the long-term effects of sustained use are not fully established in the documentation.


Q: Does taking Cervoxan make you feel tired?

General fatigue or tiredness is not explicitly listed among the most common reactions. However, the regulatory profile does document related Nervous System effects, such as dizziness and sleep disturbances.


Q: Does Cervoxan interact with common supplements like Vitamin D or magnesium?

The regulatory monographs for Cervoxan do not contain explicit interaction warnings documented for common dietary substances like food, alcohol, or herbal products. This category typically covers common vitamins and mineral supplements.


Q: How quickly does Cervoxan leave the body?

The official labeling contains detailed Pharmacokinetic properties for Vinburnine. This section describes the factual process by which the body absorbs, distributes, metabolizes, and ultimately eliminates the active ingredient.


Q: Is it normal to have mild stomach upset when first starting Cervoxan?

The most frequently cited adverse reactions involve the Gastrointestinal System, which includes reports of nausea, vomiting, and diarrhea. Since these effects are frequently cited, it suggests that mild stomach upset may be an expected pattern based on observed patient data.


Q: Is Cervoxan safe to use for teenagers?

Official regulatory documents focus on use in the adult population. Regulatory statements defining a minimum age threshold or explicit pediatric exclusion are not publicly available for citation in government-approved labeling.


Q: Does Cervoxan interact with birth control pills?

Publicly available regulatory documentation does not contain specific, detailed interaction data for Cervoxan with hormonal contraceptives. The regulatory status reflects an absence of explicit interaction claims in the public monographs.


Q: What are the most serious possible side effects listed for Cervoxan?

The official safety profile notes a risk of damage to organs from prolonged or repeated exposure as a serious constraint. Furthermore, the medicine is contraindicated, meaning it must not be used, in patients who have established severe hypotension (very low blood pressure).


Q: Can Cervoxan cause problems with sleep?

Yes, the official safety profile lists sleep disturbances as a documented adverse reaction. This is generally noted as a less common effect based on regulatory classification.


Q: Does Cervoxan interact with heart medications?

Safety constraints note that when Cervoxan is used at the same time as other medications for the heart, such as antihypertensive drugs (blood pressure lowering agents) or vasodilators, there is a potential to amplify the hypotensive effect (a greater drop in blood pressure).


Q: Is Cervoxan known to cause dependency?

Dependency or drug abuse potential is not a topic that is explicitly listed in the warnings or precautions sections of the publicly cited major regulatory monographs for this medication.


Q: Can I stop taking Cervoxan suddenly?

Specific guidance for discontinuing the treatment is included in the full official labeling. This information emphasizes that changes to treatment are part of a regulated protocol and should be discussed with a healthcare provider.


Q: Does Cervoxan affect mood or cause nervousness?

The official safety profile documents less common effects on the Nervous System that may affect a patient’s state of mind. These include reports of confusion and agitation.


Q: Does Cervoxan affect the results of any lab tests?

Publicly available regulatory documents do not detail specific interferences with common laboratory tests. The regulatory record does not specify required dose separation rules or detail exposure-modifying effects via CYP enzymes.


Q: Is there a preferred time of day to take Cervoxan?

Specific procedural requirements concerning the timing of the dose, such as relative to meals or the preferred time of day for routine use, are contained within the full official labeling.


Q: Do other medicines make Cervoxan less effective?

The official regulatory record for Cervoxan focuses on the risk of amplified effects with certain drugs. It does not contain publicly cited, specific details regarding medicinal product classes that are shown to reduce the efficacy of Cervoxan.


Q: Can Cervoxan be used by people with diabetes?

Formal restrictions or precautions concerning patients with conditions such as diabetes are not publicly cited in the available government regulatory documents. The eligibility profile is primarily structured around its classification as a cerebral vasodilator.


Q: Are there different forms of Cervoxan available (e.g., liquid, capsule)?

Cervoxan is officially available in both common oral preparations, which include tablets, capsules, and solutions/oral drops, and as a sterile injectable solution. The form used is determined by the two-stage protocol defined by regulatory authorities.


Q: What should I do if I think I'm having an allergic reaction to Cervoxan?

Hypersensitivity reactions are documented in the official safety profile. The full official labeling provides guidance on recommended actions for suspected serious reactions, which is crucial patient safety information.


Q: What happens if I miss a dose of Cervoxan?

Specific guidance for managing a missed dose is included in the patient information section of the full regulatory prescribing documents. This is part of the established use conditions defined by official authorities.


Q: Can I drive or operate machinery while taking Cervoxan?

The safety labeling provides warnings concerning the ability to drive or operate machinery. This is particularly noted due to documented adverse effects such as dizziness and confusion.

How should Cervoxan be stored and disposed of?

How to Store and Dispose of Cervoxan

The storage and disposal of Cervoxan (Vinburnine) must strictly adhere to the conditions specified in the official regulatory labeling to ensure product stability and safety.

Storage Requirements

Cervoxan must be stored at controlled room temperature and protected from excessive heat, humidity, and direct light. The medicine must be kept in its original container, and for liquid forms, it should generally not be frozen. Do not use Cervoxan after the expiration date printed on the packaging.

Disposal Instructions

Any expired or unused Cervoxan must be discarded according to local environmental rules. Do not dispose of the medicine via wastewater or household trash. Unused portions should be returned to a pharmacy or approved collection program for safe pharmaceutical waste handling.

Child Safety

It is mandatory to keep Cervoxan out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cervoxan found in:

A-Z Index: